Rate of motor progression in Parkinson's disease: a systematic review and meta-analysis

• Published in: Frontiers in neurology Vol. 15; p. 1452741
• Main Authors: Pauwels, Ayla, Phan, Albert L G, Ding, Catherine, Phan, Thanh G, Kempster, Peter A
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 26.09.2024
• Subjects: levodopa; meta-analysis; natural history; Neurology; Parkinson’s disease; progression; meta-analysis; progression; levodopa; natural history; Parkinson’s disease
• ISSN: 1664-2295; 1664-2295
• DOI: 10.3389/fneur.2024.1452741

The search for neuroprotective treatments for Parkinson's disease (PD) still relies largely on motor disability scales. A limitation of these tools is the strong influence of symptomatic dopaminergic treatment effects. Drawing on a wealth of published information, we conducted a systematic review and meta-analysis of motor progression in PD and its relationships with dopaminergic therapy. We searched Medline, Embase, and Central to identify 84 publications with adequate serial motor scores to calculate progression, expressed as an increase in the percentage of maximum disability. A random-effects model showed motor progression at 2.0% p.a. (95% CI 1.7-2.4%). There were no significant differences by baseline age, sample size, or observation period. However, untreated patients, in 8 publications, progressed at 4.5% p.a. compared to 1.6% p.a. in 76 studies containing individuals on dopaminergic drugs (  = 0.0004,  = 0.003). This was supported by research on phenoconversion in prodromal PD, where motor progression exceeded 5% p.a. in the 2 years before diagnosis. Starting levodopa improved pre-treatment disability by 40.3 ± 15.2%. Practically defined state measurements increase faster than scores by a modest degree (  = 0.05). This survey suggests that accurate long-term measurements of motor progression to assess disease-modifying therapies can be conducted despite the sequential commencement of dopaminergic drugs and sample attrition over time. While study designs involving prodromal or untreated PD avoid confounding effects of symptomatic treatment, different assumptions about motor progression may be needed. A defined state with the levodopa test dose method maximizes information about the medication cycle once dopaminergic therapy has begun.